67 results about "Revascularization" patented technology

The invention discloses a thrombus excision system. An embolus is extracted through a mechanical embolus extraction device, a blood vessel is dredged, and revascularization of the blood vessel is achieved. A saccule guide catheter is put at the near end of the embolus part when the embolus is extracted, blood flow is temporarily blocked, and thus a fine crushed embolus generated in the embolus extraction process is prevented from being flushed to the far end of the blood vessel; meanwhile, for a relatively large embolus, a part of thrombus can also be sucked by virtue of the saccule guide catheter, and then the residual thrombus can be extracted by virtue of a thrombus exsector. The thrombus exsector, the saccule guide catheter and a delivery microcatheter are arranged on the thrombus excision system disclosed by the invention, wherein the thrombus exsector is used as a main component, an excision spring is arranged, and the release state of the excision spring is a conical spiral state. Compared with the prior art, the thrombus excision system has the advantages that the thrombus exsector is very soft, the minimal through size is 0.014' (0.36mm), the thrombus exsector can easily enter a cerebral vessel, a near-end protection technology is adopted in the operation process, and thrombus suction is combined with mechanical embolus extraction, so that the success rate of the operation is improved, and the complications are reduced.

Automated image analysis used in vascular state modeling. Coronary vasculature in particular is modeled in some embodiments. Methods of “virtual revascularization” of a presently stenotic vasculature are described; useful, for example, as a reference in disease state determinations. Structure and uses of a model which relates records comprising acquired images or other structured data to a vascular tree representation are described.

Systems and methods for post-PCI coronary analysis. An example method includes accessing a plurality of angiographic images depicting at least one vessel of a patient's heart, the angiographic images including two or more post-percutaneous coronary intervention (post-PCI) images and one or more diagnostic images, wherein the post-PCI images depict a PCI location in which a PCI is included to revascularize a lesion, and wherein the diagnostic images depict the lesion; receiving, via a user interface presenting the post-PCI images, user input specifying positions of the PCI location in the post-PCI images; determining an index indicative of vascular function based on the angiographic images, wherein the index is derived based on a three-dimensional model of the portion of the patient's heart, and wherein individual portions of the diagnostic images depicting the lesion are masked during generation of three-dimensional model; and presenting, via the user interface, summary information associated with PCI, the summary information including at least the determined index.

Automated image analysis used in vascular state modeling. Coronary vasculature in particular is modeled in some embodiments. Methods of “virtual revascularization” of a presently stenotic vasculature are described; useful, for example, as a reference in disease state determinations. Structure and uses of a model which relates records comprising acquired images or other structured data to a vascular tree representation are described.

The invention provides a clinical diagnosis and treatment path generation method and system for tracking a chest pain patient. Wherein a dynamic spatio-temporal data atlas is constructed by synchronously collecting respiratory rhythm phase difference, coronary artery calcification integral and hypersensitive troponin curve slope, and risk degree transition signals are generated by coupling analysis of ST segment elevation amplitude asymmetric growth, left ventricular ejection fraction attenuation gradient and B-type natriuretic peptide release rate. In the acute stage, the constraint relation between a vascular recanalization time window and thrombolysis taboo is dynamically bound, in the subacute stage, a phase synchronization rule for enhancing CT scanning and anticoagulant drug dosage is established through a multidisciplinary interface, intravascular ultrasonic plaque morphological mutation characteristics and extracorporeal circulation parameters are fused, the blood supply reconstruction time sequence is dynamically adjusted based on a myocardial oxygen consumption balance equation, and the thrombolysis time sequence is determined. And path self-optimization is realized through space-time superposition of an interventional therapy delay parameter and a drug metabolism curve. According to the technical scheme provided by the invention, chest pain diagnosis and treatment path dynamic optimization and multi-modal parameter collaborative decision-making are realized, and the risk layering precision and the treatment timeliness are improved.

Systems and methods for post-PCI coronary analysis. An example method includes accessing a plurality of angiographic images depicting at least one vessel of a patient's heart, the angiographic images including two or more post-percutaneous coronary intervention (post-PCI) images and one or more diagnostic images, wherein the post-PCI images depict a PCI location in which a PCI is included to revascularize a lesion, and wherein the diagnostic images depict the lesion; receiving, via a user interface presenting the post-PCI images, user input specifying positions of the PCI location in the post-PCI images; determining an index indicative of vascular function based on the angiographic images, wherein the index is derived based on a three-dimensional model of the portion of the patient's heart, and wherein individual portions of the diagnostic images depicting the lesion are masked during generation of three-dimensional model; and presenting, via the user interface, summary information associated with PCI, the summary information including at least the determined index.

The invention discloses a preparation method and application of a BG (at) ZIF-8 organic-inorganic nanofiber membrane, and belongs to the field of biomedical composite materials. The method comprises the following steps: preparing BG through high-temperature calcination, wrapping the BG in ZIF-8 by using a wrapping technology to form BG-coated ZIF-8, and then carrying out microfluidic electrostatic spinning on the BG-coated ZIF-8, PCL and PVA to obtain a nanofiber membrane containing Zn < 2 + >, Ca < 2 + > and Si < 4 + > for diabetes wound healing. The ions can be slowly released to promote growth factor expression and revascularization. Experiments prove that BG (at) ZIF-8 / PCL-PVA can inhibit diabetes mellitus wound inflammation and accelerate healing. The composite fiber membrane using the micro-fluidic electrostatic spinning technology provides a new view angle for wound healing of diabetes, and is a potential efficient treatment strategy.

Devices, systems, and methods for causing retrograde oxygenated blood flow in at least a portion of the venous system of the myocardium are disclosed. Devices and methods include a method for causing retrograde oxygenated blood flow in at least a portion of the venous system of the myocardium, the method comprising: implanting a variable occluder in a coronary sinus region proximate a left atrium, wherein the variable occluder is configured to gradually increase a level of blood flow restriction over a period of days to enable a venous system of the myocardium to compensate for increased pressure caused by the gradual increase in the level of blood flow restriction; and following venous system compensation, shunting oxygenated blood flow into the coronary sinus to cause retrograde flow of oxygenated blood in at least a portion of the venous system of the myocardium to thereby enable revascularization of the myocardium.

The invention discloses an application of nitro fatty acid in preparation of a product for predicting, preventing and improving adverse cardiovascular events of patients with acute coronary syndrome. The invention provides application of nitro fatty acid in preparation of products for preventing and improving adverse cardiovascular events of ACS patients. According to the application, for the ACS patient, when the concentration of the 12-nitro conjugated linoleic acid in the body is larger than 0.196 ng / ml and the concentration of the 9-nitro conjugated linoleic acid is larger than 0.296 ng / ml, it is judged that the risk that the ACS patient is re-hospitalized and dead due to non-fatal myocardial infarction / unstable angina pectoris / blood supply reconstruction is low. By detecting the content of nitro fatty acid in a biological sample and supplementing nitro fatty acid, the occurrence rate of adverse events can be greatly reduced. Meanwhile, the invention further provides a detection method of nitro fatty acid, and the accuracy of biological sample detection is improved.

The invention discloses a temperature-controlled anti-inflammatory and antibacterial skin wound dressing capable of promoting revascularization and a preparation method and application thereof, and relates to the technical field of medical materials, the preparation method comprises the following steps: S1, preparing calcium peroxide microspheres; s2, the poloxamer 407, the chitosan and the forsythiaside A are jointly dissolved in an acetic acid solution, and mixed gel is obtained; s3, dispersing calcium peroxide microspheres into the mixed gel to obtain the skin wound dressing capable of controlling temperature, resisting inflammation and bacteria and promoting revascularization. The traditional Chinese medicine active ingredient forsythiaside A is loaded, so that the healing efficiency of diabetic wounds is improved; due to the temperature-sensitive property of the gel, the gel can be better attached to the wound, the antibacterial property can inhibit microorganism breeding at the wound surface, the oxygen release capacity can improve the anoxic environment at the wound, and the loaded traditional Chinese medicine active ingredient forsythiaside A has the anti-inflammatory capacity, promotes cell regeneration at the wound and accelerates the repair process.

The invention discloses a medicinal preparation for promoting healing of chronic diabetic wounds as well as a preparation method and application of the medicinal preparation, and relates to the technical field of medicinal preparations. According to the invention, a thrombin solution containing Se-CQDs and a fibrinogen solution containing GOX are mixed and reacted to prepare the pharmaceutical preparation for promoting healing of chronic wounds of diabetes. The pharmaceutical preparation for promoting healing of the chronic wound of diabetes can effectively remove excessive ROS at the chronic wound of diabetes and reduce the pH, glucose content and M1 / M2 macrophage proportion at the chronic wound, so that the high-glucose alkaline inflammation microenvironment of the chronic wound of diabetes is reversed, collagen deposition, revascularization and skin tissue reepithelization are promoted, and the healing of the chronic wound of diabetes is promoted. Therefore, healing of chronic diabetic wounds is promoted. Meanwhile, Se-CQDs and GOX are combined to prepare the pharmaceutical preparation, and the pharmaceutical preparation has a synergistic effect on promoting healing of chronic wounds of diabetes mellitus.

A tissue graft for soft tissue repair or reconstruction comprising a sheet of a biopolymer-based matrix having a plurality of small perforations and a plurality of large perforations. The small perforations are sized to facilitate clotting and granulation tissue development within the perforations which, in turn, facilitates revascularization and cell repopulation in the patient. The large perforations are sized to reduce the occurrence of clotting and granulation tissue development within the perforations so that extravascular tissue fluids accumulating at the implant site can drain through the tissue graft. The large perforations enhance mammal tissue anchoring by permitting mammal tissue to compress into the perforations increasing mammal tissue contact area.

This invention discloses a magnetically controlled balloon guidewire for microvascular revascularization and its manufacturing method. The magnetically controlled balloon guidewire for microvascular revascularization includes a magnetically controlled tip, a phase-change balloon, and a guidewire connected in sequence. This magnetically controlled balloon guidewire for microvascular revascularization can precisely navigate and flexibly steer, and the phase-change balloon can accurately navigate to the stenotic lesion site of the microvessel.

The present invention provides extracellular vesicle compositions. Also provided are methods of making an extracellular vesicle loaded scaffold using the extracellular vesicle compositions to increase revascularization. Methods of using the extracellular vesicle compositions and the extracellular vesicle loaded scaffold are provided. The scaffold may increase blood flow and oxygenation of the tissue thereby aiding in treatment of disease and injury.

Provided herein are compositions including a CRISPR / dCas9-based demethylation cocktail targeting a methylated endothelial PLCγ2 promoter and methods of treating wounds using the same.

Reperfusion injury is limited during endovascular therapies (e.g., revascularization and / or reperfusion of end organ tissues) by conditioning the tissues against reperfusion injury using an optical fiber catheter to deliver far red and near infrared (R / NIR) light to the tissues. The light may be multiple wavelength or single wavelength light, and may have one or more wavelengths selected from the range of 510 to 830 nm. The R / NIR light may be delivered concurrently with the endovascular therapy, or in other instances may be delivered before or after a particular therapy.

The subject invention pertains to a novel method for treating Peripheral Arterial Disease (PAD) by leveraging the angiogenic potential oftype 2 cytokines IL-4 and IL-13 to enhance the efficacy of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and induced endothelial cells derived from fibroblasts (iECs). This present invention aims at enhancing the muscle regeneration and revascularization for obese and diabetes individuals.

The invention discloses a post-AMI heart failure oxidized lipid screening method based on solid phase extraction, LC-MS / MS and AI. The method comprises the steps of blood sample pretreatment, solid phase extraction and purification, LC-MS / MS detection and AI model screening. According to the method, high-sensitivity qualitative and quantitative detection of oxidized lipid is realized through optimized LC-MS / MS parameters, and key oxidized lipid molecules and risk levels of heart failure after AMI emergency treatment blood supply reconstruction can be quickly and accurately screened in combination with a trained random forest AI model; the kit solves the problems that in the prior art, trace oxidized lipid detection sensitivity is low, specificity is poor, and heart failure risk screening lags, has the advantages of being high in detection efficiency, good in accuracy and high in practicability, can provide a scientific basis for early warning and intervention of clinical heart failure after AMI, and has high clinical application value.

Processes are provided based on an interventional (device-based) approach to minimize the development of intramyocardial hemorrhage within the myocardial infarction (MI) zone. In one exemplary process, the revascularization occurs in an incremental fashion prior to fully opening the vessel, so as to modulate the hydrostatic pressure transmitted from the proximal end of the catheter, prior to placing a stent. In another exemplary process, the stent will be placed within the central core of the embolization and will slowly expand within the lumen reaching full patency over a period of time. Devices operated with these processes can also greatly reduce the chance of development of intramyocardial hemorrhage with the MI zone. These developments can improve the outcome in hemorrhagic patients, who otherwise carry a significant risk for heart failure and sudden death.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.

Devices, systems, and methods for causing retrograde oxygenated blood flow in at least a portion of the venous system of the myocardium are disclosed. Devices and methods include a method for causing retrograde oxygenated blood flow in at least a portion of the venous system of the myocardium, the method comprising: implanting a variable occluder in a coronary sinus region proximate a left atrium, wherein the variable occluder is configured to gradually increase a level of blood flow restriction over a period of days to enable a venous system of the myocardium to compensate for increased pressure caused by the gradual increase in the level of blood flow restriction; and following venous system compensation, shunting oxygenated blood flow into the coronary sinus to cause retrograde flow of oxygenated blood in at least a portion of the venous system of the myocardium to thereby enable revascularization of the myocardium.

This invention provides a blood revascularization monitoring device and method. The blood revascularization monitoring device includes: a light source and a photoelectric sensor disposed on a housing; both the light source and the photoelectric sensor are electrically connected to a main control board inside the housing; the light source includes a first light-emitting diode; the photoelectric sensor includes a first receiver and a second receiver; the first receiver and the second receiver, together with the first light-emitting diode, form a first monitoring channel for monitoring blood oxygen data; the line connecting the first receiver and the second receiver forms a triangle with the projection of the first monitoring channel onto the bottom surface of the housing. This invention facilitates accurate monitoring of blood circulation status.

Disclosed are devices, systems and methods for myocardial revascularization, including endovascular medical devices for shunting and selectively regulating anatomical fluid flow. A tubular shunt is configured to be placed in a passage between a first organ and an adjacent second organ and bridge a first cavity of the first organ and a second cavity of the second organ. A stabilizer is configured to stabilize the tubular shunt in the passage. A flow deflector extends from the tubular shunt and has a surface for deflecting flow in the second cavity.

A system for removing a thrombus in a blood vessel, includes: a main body part which is movable along the blood vessel and performs a revascularization function within the blood vessel during installation, and sucks and transfers the thrombus during aspiration; a microflow circuit part which is attached to the outer surface of the main body part and extends to the exterior of the body, creates a microflow circuit which acts on the thrombus to move, deform, and fragment the thrombus; and an aspiration part which is provided to the exterior of the body from the inside of the blood vessel, and which during aspiration, after blocking blood flow in the blood vessel, aspirates the thrombus which has been moved, deformed and fragmented by the microflow circuit part and transferred by the main body part and discharges the thrombus to the outside of the body.

The invention discloses photosensitive multifunctional tri-crosslinked hydrogel GM / OD-coated PRP, a preparation method and application thereof, and relates to the technical field of hydrogel, and the preparation method comprises the following steps: (1) preparing methacrylated gelatin GM; (2) preparing oxidized dextran OD; (3) preparing platelet rich plasma (PRP); and (4) preparing the GM / OD-coated PRP tri-crosslinked hydrogel. In the invention, the GM can form an optical cross-linked network, the three-network composite hydrogel is formed by introducing OD, utilizing Schiff base reaction and combining amino groups in the GM and PRP, and the three-network composite hydrogel is used as a physical protection barrier to prevent digestive juice from overflowing and is used for preventing anastomotic fistula. According to the composite hydrogel, due to the addition of the PRP, the hydrogel is endowed with the capability of multiple growth factors at the same time, and the healing of an anastomotic stoma is promoted and the occurrence of anastomotic fistula is prevented by promoting cell proliferation, revascularization and vascularization. The GM / OD-coated PRP hydrogel has excellent bacteriostatic ability to staphylococcus aureus and escherichia coli, so that intestinal bacteria displacement can be prevented, and infection in the abdominal cavity is avoided.

Devices, systems, and methods for causing retrograde oxygenated blood flow in at least a portion of the venous system of the myocardium are disclosed. Devices and methods include a method for causing retrograde oxygenated blood flow in at least a portion of the venous system of the myocardium, the method comprising: implanting a variable occluder in a coronary sinus region proximate a left atrium, wherein the variable occluder is configured to gradually increase a level of blood flow restriction over a period of days to enable a venous system of the myocardium to compensate for increased pressure caused by the gradual increase in the level of blood flow restriction; and following venous system compensation, shunting oxygenated blood flow into the coronary sinus to cause retrograde flow of oxygenated blood in at least a portion of the venous system of the myocardium to thereby enable revascularization of the myocardium.

Ischemic heart disease is a leading cause of death and reduced quality of life worldwide. Although revascularization strategies significantly reduce mortality after acute myocardial infarction (MI), many patients with MI develop chronic heart failure over time. We previously reported that human recombinant ANGPTL4 counteracts ischemia-induced vascular endothelial growth factor signaling and disruption of endothelial cell-cell adhesion, thereby inhibiting vascular permeability. We were able to demonstrate that ANGPTL4 administration before MI resulted in protection of the coronary capillary network, no-reflow syndrome, and reduced infarct size in mice. We also demonstrated that the therapeutic effects observed with ANGPTL4 under ischemic conditions were caused by the FLD fragment, not the CCD fragment (WO 2016 / 110498). To further examine the therapeutic potential of the FLD fragment of ANGPTL4 at the onset of reperfusion, we herein used a porcine model, a clinically relevant model of acute myocardial infarction that can be easily and safely translated into patient treatment. We demonstrated that local (antegrade) delivery of the FLD ANGPTL4 to infarcted porcine hearts can efficiently target the lesion site in a clinically relevant manner. A single administration of the FLD of ANGPTL4 improved cardiac function, infarct size, fibrosis, and adverse remodeling parameters 28 days after MI. Short-term MI experiments, coupled with complementary mouse studies, demonstrated myocardial protection. Thus, a single administration of the FLD of ANGPTL4 can reduce ischemia-reperfusion injury and protect against adverse postischemic cardiac remodeling and subsequent ischemic heart failure.

A method of removing vascular blockage includes providing a catheter system, comprising an outer catheter, a bypass catheter, and a guidewire. In the catheter system, the bypass catheter is slidably disposed within the outer catheter. The method includes positioning a distal end of the catheter system at a proximal end of an occlusion located within a vessel and moving the bypass catheter through the occlusion so that a medicated treatment solution may be delivered through the bypass catheter to an area of the brain or other tissue served by the vessel blocked by the occlusion. Both during and after the delivery of medicated treatment solution to the blocked part of the vessel with the bypass catheter, the physician may engage the occlusion with the perforated segment of the outer catheter so that a thrombolytic agent can be delivered at the occlusion to disintegrate it and then removing at least a portion of the occlusion from the vessel.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.